CompletedPhase 2NCT02152137
Inolitazone Dihydrochloride and Paclitaxel in Treating Patients With Advanced Anaplastic Thyroid Cancer
Studying Anaplastic thyroid carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Alliance for Clinical Trials in Oncology
- Principal Investigator
- Robert Smallridge, M.D., MD PhD FACPMayo Clinic
- Intervention
- efatutazone(drug)
- Enrollment
- 19 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2014 – 2023
Study locations (30)
- Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States
- Anchorage Radiation Therapy Center, Anchorage, Alaska, United States
- Alaska Breast Care and Surgery LLC, Anchorage, Alaska, United States
- Alaska Oncology and Hematology LLC, Anchorage, Alaska, United States
- Alaska Regional Hospital, Anchorage, Alaska, United States
- Alaska Women's Cancer Care, Anchorage, Alaska, United States
- Anchorage Oncology Centre, Anchorage, Alaska, United States
- Katmai Oncology Group, Anchorage, Alaska, United States
- Providence Alaska Medical Center, Anchorage, Alaska, United States
- Mayo Clinic Hospital, Phoenix, Arizona, United States
- Mayo Clinic in Arizona, Scottsdale, Arizona, United States
- Providence Saint Joseph Medical Center/Disney Family Cancer Center, Burbank, California, United States
- University of Colorado Hospital, Aurora, Colorado, United States
- Smilow Cancer Hospital Care Center at Saint Francis, Hartford, Connecticut, United States
- Smilow Cancer Center/Yale-New Haven Hospital, New Haven, Connecticut, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
National Cancer Institute (NCI) · Daiichi Sankyo
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02152137 on ClinicalTrials.govOther trials for Anaplastic thyroid carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06790706IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE CancersHospices Civils de Lyon
- RECRUITINGPHASE1NCT06902376XL092 and Cemiplimab in BRAF WT Thyroid CancerUNC Lineberger Comprehensive Cancer Center
- RECRUITINGPHASE2NCT06235216Sacituzumab govitEcan in THYroid CancersGrupo Espanol de Tumores Neuroendocrinos
- RECRUITINGPHASE2NCT06362694Study of the Rechallenge Concept in Patients With BRAF-positive Anaplastic Thyroid Cancer After Progression on Anti-BRAF TherapySaint Petersburg State University, Russia
- RECRUITINGPHASE2NCT06374602Efficacy of Pembrolizumab and Lenvatinib in Patients With Anaplastic Thyroid CancerSaint Petersburg State University, Russia
- RECRUITINGPHASE2NCT06007924A Study of Avutometinib and Defactinib in People With Thyroid CancerMemorial Sloan Kettering Cancer Center
- RECRUITINGPHASE2NCT06079333NEO- and Adjuvant Targeted Therapy in Braf-mutated Anaplastic Cancer of the Thyroid (NEO-ATACT Study)Leiden University Medical Center
- ACTIVE NOT RECRUITINGPHASE2NCT05453799Vudalimab for the Treatment of Locally Advanced or Metastatic Anaplastic Thyroid Cancer or Hurthle Cell Thyroid CancerNorthwestern University